Please assess the completion status of the following clinical trial:

Trial Title: A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent~* General good health~* Persistent asthma, with an FEV1 50-80% predicted.~* Ability to perform spirometry in an acceptable manner as per protocol guidelines.~* Ability to perform PEFR with a handheld peak flow meter.~* Demonstration of reversible bronchoconstriction as verified by a 15% or greater increase from baseline FEV1.~* Taking inhaled corticosteroids at a stable dose for at least 4 weeks prior to the Screening Visit.~* Non-smokers.~* Capable of understanding the requirements, risks, and benefits of study participation.~* Other inclusion criteria apply.~Exclusion Criteria:~* Participation in any investigational drug trial within the 30 days preceding the Screening Visit (SV).~* A known hypersensitivity to albuterol or any of the excipients in the formulations.~* History of severe milk protein allergy.~* History of a respiratory infection or disorder that has not resolved within the 2 weeks preceding the Screening Visit (SV).~* Currently requires treatment with β2-adrenergic receptor antagonists or non-selective β-receptor blocking agents.~* History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.~* Any asthma exacerbation requiring oral corticosteroids within 3 months of the Screening Visit (SV). A subject must not have had any hospitalization for asthma within 6 months prior to the Screening Visit (SV).~* Historical or current evidence of any clinically significant non-asthmatic acute or chronic condition including.~* Other exclusion criteria apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo MDPI (Type: PLACEBO_COMPARATOR): Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
- Albuterol MDPI (Type: EXPERIMENTAL): Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).